 |
 |
|||||||||||||||
 |
||||||||||||||||
|
||||||||||||||||
|
||||||||||||||||
|
Oncolytics has completed seven clinical trials with REOLYSIN® in Canada, the U.K. and the U.S. and is currently enrolling or recruiting patients in ten Phase I/II or Phase II REOLYSIN® trials in the U.K. and the U.S. The current clinical program includes local or systemic delivery of REOLYSIN® as a monotherapy, and local or systemic delivery of REOLYSIN® in combination with radiation, chemotherapy or immune modulation for patients with advanced cancers.
* REOLYSIN® is a registered trade mark owned by Oncolytics Biotech Inc. and is registered in Canadian and US Trade Mark offices.
|
|
|||||||||||||||||||||||||||||||||
 |
|
 |